Benzinga··NaNovartis to Acquire Excellergy for Up to $2B, Bolstering Anti-IgE Allergy Portfolio
Novartis to acquire private biotech Excellergy for up to $2B, adding next-generation anti-IgE antibody Exl-111 targeting food allergy, chronic urticaria, and allergic asthma.
NVSacquisitionbiotech